Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial*
References (31)
- et al.
High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study
Lancet
(2001) - et al.
Efficacy of cholesterol levels and ratios in predicting future coronary heart disease in a Chinese population
Am J Cardiol
(2001) - et al.
Epidemiologic aspects of lipid abnormalities
Am J Med
(1998) - et al.
Plasma lipids and cardiovascular risk: A POSCH report. Program on the Surgical Control of the Hyperlipidemias
Atherosclerosis
(2001) - et al.
Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholes terolemia and without active arterial disease
Am J Cardiol
(2003) - et al.
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)
Am J Cardiol
(2003) - et al.
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia
Am Heart J
(2002) - et al.
Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial
Am Heart J
(2002) - et al.
Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT). I. Use of a dietary monitoring tool
J Am Diet Assoc
(1980) - et al.
A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol
J Lipid Res
(1978)
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study
Am Heart J
Atorvastatin Comparative Cholesterol Efficacy and Safety Study. Correlation of nonhigh-density lipoprotein cholesterol with apolipoprotein B: Effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels
Am J Cardiol
Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment
Lancet
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
Circulation
Non-highdensity lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI)
Circulation
Cited by (104)
Current and future options in cholesterol lowering treatments
2023, European Journal of Internal MedicineStatin Pretreatment Might Be Associated with Decreased Myocardial Injury After Ischemic Stroke
2020, Journal of Stroke and Cerebrovascular DiseasesFamilial combined hyperlipidemia and hyperlipoprotein(a) as phenotypic mimics of familial hypercholesterolemia: Frequencies, associations and predictions
2016, Journal of Clinical LipidologyCitation Excerpt :A previously described FCHL nomogram was used to assess the frequency of FCHL in mutation-negative patients (Supplementary Fig. 1).14 As this nomogram relies on untreated lipid levels, and because 52.5% of patients were on lipid-lowering medication at the time of measurement, lipid levels were treatment adjusted based on previously described effects of statins and/or ezetimibe.29–36 The correction factors implemented for each treatment regime are listed in Supplementary Table 1.
A method to estimate the contribution of rare coding variants to complex trait heritability
2024, Nature CommunicationsApoB100 and Atherosclerosis: What’s New in the 21st Century?
2024, MetabolitesRisk of Venous Thromboembolism with Statins: Evidence Gathered via a Network Meta-analysis
2023, Balkan Medical Journal
- *
Data from this study were presented in part at the European Society of Cardiology Congress 2003, August 30–September 3, 2003, Vienna, Austria; and at the XIII International Symposium on Atherosclerosis, September 28–October 2, 2003, Kyoto, Japan.
- *
Current affiliation: AstraZeneca LP, Wilmington, Delaware.